Mohammed Rehab A, Garout Rana M, Wahid Sherehan, Ayub Fatema, Firas ZinAlddin Leen M, Sultan Intessar
Internal Medicine, Ibn Sina National College for Medical Studies, Jeddah, SAU.
Internal Medicine, Al-Azhar University Faculty of Medicine for Girls, Cairo, EGY.
Cureus. 2021 Nov 3;13(11):e19222. doi: 10.7759/cureus.19222. eCollection 2021 Nov.
Pfizer-BioNTech vaccine was the first of all coronavirus disease (COVID) vaccines to be used in Saudi Arabia. There have been over 17 million doses already administered to the general public in order to successfully reach herd immunity.
The study aimed to explore the side effects of the Pfizer-BioNTech vaccine.
This is a cross-sectional study comprising a sample of 386 participating adults of different age groups and genders. A validated modified questionnaire was distributed as a Google form to residents of the kingdom via social networking sites from February to March 2021. The questionnaire included questions regarding participants' socio-demographic details, vaccination details, and symptom analyses items.
The most common to least reported symptoms were local pain (79.3%), fatigue (42%), muscle pain (39.1%), local swelling (27.7%), joint pain (23.1%), headache (21.8%), fever (21.0%), chills (15.5%), local redness (14.8%), nausea (7.3%), with no reports of anaphylaxis, facial paralysis or syncope. There were more side effects after the second dose than the first (p<0.001). Significant predictors of a higher number of side effects after both doses of the vaccine were the female gender ((p<0.001)) and the presence of allergies (p=0.044).
Pfizer/BioNTech vaccination was quite safe with no reported anaphylaxis or serious events. The most common reported side effects were local pain and fatigue. Symptoms began within 24 hours and were mild to moderate in nature with a regressive course, especially after analgesics. More side effects were experienced after the second dose than the first. The significant predictors of side effects were the female gender and a history of allergies.
辉瑞 - 生物科技公司的疫苗是沙特阿拉伯使用的首款新冠疫苗。为成功实现群体免疫,已向公众接种了超过1700万剂该疫苗。
本研究旨在探讨辉瑞 - 生物科技公司疫苗的副作用。
这是一项横断面研究,样本包括386名不同年龄组和性别的参与研究的成年人。2021年2月至3月,通过社交网站以谷歌表单的形式向沙特王国居民发放了一份经过验证的改良问卷。问卷包括有关参与者社会人口学细节、疫苗接种细节和症状分析项目的问题。
报告频率从高到低的最常见症状依次为局部疼痛(79.3%)、疲劳(42%)、肌肉疼痛(39.1%)、局部肿胀(27.7%)、关节疼痛(23.1%)、头痛(21.8%)、发热(21.0%)、寒战(15.5%)、局部发红(14.8%)、恶心(7.3%),未报告有过敏反应、面瘫或晕厥病例。第二剂疫苗接种后的副作用比第一剂更多(p<0.001)。两剂疫苗接种后副作用数量较多的显著预测因素是女性(p<0.001)和有过敏史(p = 0.044)。
辉瑞/生物科技公司的疫苗接种相当安全,未报告有过敏反应或严重事件。报告的最常见副作用是局部疼痛和疲劳。症状在24小时内出现,性质为轻至中度,呈逐渐消退过程,尤其是在使用镇痛药后。第二剂疫苗接种后的副作用比第一剂更多。副作用的显著预测因素是女性和过敏史。